Palvella Therapeutics, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
Palvella Therapeutics, Inc. (PVLA) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $2.62 million as of 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2024-03-29
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $2.62M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $3.11M.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $2.74M.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $2.91M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits as first filed |
|---|---|---|
| 2023-12-31 | $2.62M 10-K · filed 2024-03-29 | |
| 2022-12-31 | $3.11M 10-K · filed 2024-03-29 | |
| 2021-12-31 | $2.74M 10-K · filed 2023-03-31 | |
| 2020-12-31 | $2.91M 10-K · filed 2022-03-02 | |
| 2019-12-31 | $2.71M 10-K · filed 2021-03-31 | |
| 2018-12-31 | $2.36M 10-K · filed 2020-03-13 | |
| 2017-12-31 | $1.28M 10-K · filed 2019-03-18 | |
| 2016-12-31 | $1.08M 10-K · filed 2018-03-15 | $1.08M 10-K · filed 2017-03-30 |
| 2015-12-31 | $692.91K 10-K · filed 2017-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |